// App-Quantinova.ai

CT553 : Tislelizumab (TIS versus docetaxel (D in patients with previously treated advanced non-squamous (non-sq non-small-cell lung cancer (NSCLC: Subanalysis from the RATIONALE-303 phase 3 randomized clinical study

Researchers

Presenter

  • Ying Cheng

Principal Investigators

  • Dingzhi Huang

  • Zhiyong Ma

  • Yun Fan

  • Jie Wang

  • Xinmin Yu

  • Mikhail Dvorkin

  • Gareth Rivalland

  • Yiyuan Ma

  • Yan Wang

  • Yan Ma

  • Caicun Zhou

Medical Centers

  • Department of Medical Thoracic Oncology, Jilin Cancer Hospital, Changchun/CN

  • Department of Thoracic Medical Oncology, Lung Cancer Diagnosis and Treatment Center, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin/CN

  • Department of Immunology, Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, China

  • Breast Cancer Center, Cancer Hospital of the University of Chinese Academy of Sciences, Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China

  • Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

  • BHI of Omsk Region, Clinical Oncology Dispensary, Omsk, Russia

  • Department of Oncology, Auckland City Hospital, Auckland, New Zealand

  • BeiGene, Beijing, China

  • Department of Lung Cancer and Immunology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China

Locations

  • China

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Non Small Cell Lung cancer

Biomarkers

  • Programmed death-ligand 1

Drug/Treatment

  • Tislelizumab

  • Docetaxel

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • III

Study Id's

  • NCT03358875

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved